ARTVIGIL 250

What is ARTVIGIL 250?

ARTVIGIL 250 is a modern medicinal preparation from the group of nootropics and wakefulness-promoting agents, the active substance of which is armodafinil. The product is available in the form of tablets for oral administration with a fixed dosage of 250 mg, providing a predictable pharmacological response of the body. The manufacturer of the drug is Signature, a company known for producing high-quality generics with controlled bioavailability. ARTVIGIL 250 belongs to the category of other generics and nootropics and is used under medical supervision for the correction of disorders associated with excessive sleepiness. A specialist consultation is mandatory before starting therapy, as the body's reaction to armodafinil may be individual.

The pharmacological action of ARTVIGIL 250 is aimed at stimulating wakefulness centers in the brain without the classic excitatory effect inherent in amphetamine-like compounds. Armodafinil, as the enantiomer of modafinil, is characterized by a longer duration of action and a more stable plasma concentration profile. Thanks to this, the drug helps maintain attention levels, reduce daytime sleepiness, and improve cognitive performance in patients with appropriate indications. The tablet form ensures convenience of intake and accurate dosing of the active substance. The quality of Signature products is confirmed by generic manufacturing standards oriented towards the reproducibility of the therapeutic effect.

In clinical practice, ARTVIGIL 250 is considered a support tool for pathological sleepiness syndromes when standard sleep hygiene measures prove insufficient. The drug does not replace full sleep and does not eliminate the root cause of the disorder; it merely modulates the state of wakefulness throughout the day. It is important for patients to understand that efficacy and safety depend on proper dose selection, concomitant diseases, and interactions with other medications. The individual response of the body may vary, making self-medication unacceptable. The decision to prescribe ARTVIGIL 250 is made solely by a physician after evaluating the medical history and, if necessary, additional examinations.

What is ARTVIGIL 250 prescribed for?

The main indication for the use of ARTVIGIL 250 is excessive daytime sleepiness in narcolepsy — a chronic neurological disorder in which the control of the sleep-wake cycle is impaired. The drug helps reduce episodes of sudden daytime sleepiness and maintain working capacity without replacing nighttime sleep. The doctor assesses the severity of symptoms, the presence of cataplexy, and concomitant disorders before selecting a regimen. ARTVIGIL 250 can be part of complex therapy along with sleep hygiene and behavioral recommendations. The effect develops gradually and requires regular monitoring by a specialist.

Another important indication is shift work sleep disorder, where the work schedule shifts the natural circadian rhythm, causing persistent sleepiness during working hours. ARTVIGIL 250 helps maintain alertness during periods of forced wakefulness, reducing the risk of fatigue-related errors. Prescription is appropriate only with a confirmed diagnosis and after excluding other causes of hypersomnia. Patients are advised to combine pharmacotherapy with the optimization of rest regimens between shifts. The duration of the course and the dose are adjusted by the doctor depending on response and tolerability.

ARTVIGIL 250 is also used in obstructive sleep apnea as an adjunctive agent to reduce residual daytime sleepiness against the background of primary therapy (such as CPAP). The drug does not cure apnea and does not replace hardware methods, but only improves the state of wakefulness if sleepiness persists. Indications are determined by a somnologist or neurologist after instrumental diagnostics. In all cases, an in-person consultation is required before taking it, as armodafinil has a specific safety profile. Individual sensitivity to the active substance can affect the intensity of the effect and the occurrence of adverse reactions.

Composition and active ingredients of ARTVIGIL 250

The active substance of ARTVIGIL 250 is armodafinil at a dose of 250 mg per tablet. Armodafinil is the R-enantiomer of modafinil and features a longer elimination half-life, which provides more even support for wakefulness throughout the day. The mechanism of action is linked to its effect on neurotransmitter systems, specifically by increasing the activity of dopaminergic and orexinergic pathways in structures responsible for the sleep-wake cycle. The drug is not a classic psychostimulant and usually does not cause pronounced euphoria at therapeutic doses. Excipients of the tablet ensure stability, solubility, and convenience of oral intake without altering the main pharmacodynamics of armodafinil.

After taking ARTVIGIL 250, armodafinil is well absorbed in the gastrointestinal tract, reaching peak plasma concentrations within a few hours. Metabolism occurs primarily in the liver with the participation of cytochrome enzyme systems, which is important to consider during concomitant pharmacotherapy. Excretion of metabolites is carried out by the kidneys, so the functional state of the liver and kidneys affects dose selection. The bioavailability of Signature's generic is aimed at reproducing the profile of original armodafinil preparations. For patients with metabolic disorders, the doctor may recommend additional monitoring of laboratory parameters.

Understanding the composition of ARTVIGIL 250 helps assess the risks of allergy to excipients and potential interactions. Individuals with intolerance to specific fillers must inform their physician before starting treatment. The active component acts systemically, so the effect and side effects may manifest not only in the nervous system, but also in the cardiovascular and digestive systems. Any changes in well-being during administration require medical evaluation. Self-adjustment of the dose or regimen is unacceptable due to the individual variability of the body's response.

Dosage of ARTVIGIL 250

The recommended dose of ARTVIGIL 250 for adults is usually one 250 mg tablet per day, but the exact dosage is determined individually by a physician. For narcolepsy and residual sleepiness in apnea, administration is most often planned in the morning to cover the daytime period of activity. For shift work sleep disorder, the time of administration is aligned with the start of the work shift. Increasing the dose beyond prescribed levels does not increase the safety of the effect and may exacerbate side effects. Dose adjustment is required for elderly patients and individuals with impaired liver function.

The duration of the ARTVIGIL 250 course depends on the clinical situation, symptom dynamics, and tolerability. The doctor periodically evaluates the need to continue therapy, possible dose reduction, or breaks. Abrupt self-discontinuation usually does not cause classic withdrawal syndrome, unlike some stimulants; however, it is better to agree on a plan for ending treatment with a specialist. For patients with concomitant heart, vascular, or psychiatric disorders, the dosage is selected with particular caution. Follow-up visits allow for timely detection of undesirable effects and adjustment of the regimen.

In individual cases, the doctor may start therapy with a lower dose followed by an increase to 250 mg if justified by the safety profile. For children and adolescents, ARTVIGIL 250 is generally not prescribed without special indications and only within the competence of a specialist. For pregnant and breastfeeding women, dosages are not routinely selected — the issue is resolved only for life-saving indications. Any change in the administration regimen must be documented and justified. A doctor's consultation is mandatory before starting treatment, taking into account the individual reaction of the body.

How to properly take ARTVIGIL 250?

ARTVIGIL 250 is taken orally, washed down with a sufficient amount of water, without chewing the tablet unnecessarily. It is desirable to take it at the same time of day as prescribed to maintain a stable concentration of armodafinil. Food may slightly delay absorption, so if a faster effect is required, the drug is sometimes recommended on an empty stomach, but specific instructions are given by the doctor. You should not combine administration with large amounts of caffeine without agreement to avoid excessive nervous excitability. Compliance with instructions reduces the risk of fluctuations in efficacy throughout the day.

If a dose of ARTVIGIL 250 is missed, do not double the next dose. If there are many hours left until the usual time of administration, the missed dose can be taken; if it is close to the next administration, skip the missed one. Taking a missed dose in the evening to "catch up" can disrupt night sleep and cause insomnia. Patients are recommended to keep a log of intake and well-being, especially at the start of therapy. Any doubts about the scheme should be discussed with a doctor, rather than changing the regimen independently.

Precautions when taking ARTVIGIL 250 include monitoring blood pressure and paying attention to the onset of anxiety, headaches, or skin reactions. The drug does not replace a sleep routine: it is necessary to maintain a sufficient duration of night rest as much as the diagnosis allows. Alcohol during treatment is undesirable due to increased liver load and possible distortion of the effect. Driving at the start of therapy requires caution until the individual reaction is determined. Consultation with a doctor is required before making any changes to the method of administration.

Side effects of ARTVIGIL 250

Common side effects of ARTVIGIL 250 include headache, nausea, dry mouth, nervousness, insomnia, and decreased appetite. These phenomena often occur at the beginning of the course and may decrease as the body adapts. Patients are advised to inform their physician of persistent or worsening symptoms, even if they seem "usual" for stimulating agents. Dizziness, palpitations, or dyspepsia are sometimes observed. Assessment of the benefit-to-risk ratio is carried out individually.

Uncommon side effects of ARTVIGIL 250 may include increased blood pressure, anxiety states, mood changes, skin rashes, and gastrointestinal disorders. Less frequently, allergic reactions, severe dermatological manifestations, and clinically significant changes in liver laboratory values are described. The appearance of a rash, edema, difficulty breathing, or a sharp deterioration in health requires immediate discontinuation of intake and seeking medical help. Individuals with a psychiatric history require enhanced supervision. Any atypical reaction must be documented and evaluated by a specialist.

You should consult a doctor in case of persistent insomnia, chest pain, severe anxiety, depressive episodes, jaundice, or signs of hypersensitivity. Continuing to take ARTVIGIL 250 independently amidst serious symptoms is dangerous. The doctor may reduce the dose, temporarily discontinue the drug, or change the treatment regimen. The individual response of the body is not always predictable, even at a standard dose of 250 mg. Regular feedback with a clinician is key to safe therapy.

Contraindications of ARTVIGIL 250

Absolute contraindications to ARTVIGIL 250 are hypersensitivity to armodafinil, modafinil, or any component of the tablet, as well as uncontrolled severe arterial hypertension and certain serious heart rhythm disorders as decided by the physician. The drug is not used if there is a history of known severe allergic reactions to similar agents. Acute psychotic states and unstable mental disorders may also preclude prescription. The decision is always based on an in-person risk assessment. Independent initiation of therapy in the presence of contraindications is unacceptable.

Relative contraindications of ARTVIGIL 250 include liver and kidney diseases, cardiovascular pathology, glaucoma, thyrotoxicosis, and a tendency toward anxiety disorders. In such cases, prescription is possible only for strict indications with an adjusted dose and monitoring. Elderly patients require caution due to altered metabolism and a higher risk of interactions. Individuals taking drugs with a narrow therapeutic window need special attention. Any concomitant disease must be reported to the doctor before issuing a prescription.

Pregnancy and breastfeeding are periods when ARTVIGIL 250 is generally not recommended due to insufficient data on safety for the fetus and infant. The product is not routinely prescribed to children and adolescents. Women of reproductive age should discuss contraception, as armodafinil can reduce the effectiveness of certain hormonal contraceptives. Pregnancy planning during therapy requires advance agreement with a doctor. A consultation is mandatory before administration, as individual reaction and health status determine the admissibility of treatment.

Interaction of ARTVIGIL 250 with other drugs and alcohol

ARTVIGIL 250 can affect hepatic enzyme activity, altering blood concentrations of other medicinal products. Particular attention is required for hormonal contraceptives, anticoagulants, certain anticonvulsants, antidepressants, and drugs with a narrow therapeutic index. Concomitant administration with other central nervous system stimulants increases the risk of nervousness, tachycardia, and insomnia. The patient is obliged to provide the physician with a full list of medications and supplements, including over-the-counter ones. Adjustment of concomitant therapy or additional monitoring may be necessary for the safe use of ARTVIGIL 250.

Compatibility of ARTVIGIL 250 with alcohol is unfavorable: ethanol increases the load on the liver, can distort the subjective feeling of wakefulness, and impair attention control. Even small doses of alcohol during therapy increase the risk of dizziness and errors when driving or operating machinery. At the start of the course, drivers and complex equipment operators are recommended to refrain from responsible tasks until their individual reaction is determined. Any doubts regarding drug combinations should be resolved solely with a doctor. Ignoring interactions can reduce treatment efficacy or cause complications.

Where to buy ARTVIGIL 250 in Ukraine

ARTVIGIL 250 in Ukraine is sold through pharmacy chains and licensed online pharmacies upon presentation of appropriate dispensing documentation defined by current rules for the circulation of such agents. Before purchasing, it is advisable to clarify the availability of the specific 250 mg dosage manufactured by Signature and check the expiration date and package integrity. The drug must be stored in a dry place, protected from direct light and inaccessible to children, at the temperature specified by the manufacturer. Delivery by pharmacy services is usually possible within the rules of transportation for medicines, without violating cold or humidity conditions if required. You should not purchase the drug from questionable sources without quality guarantees.

Before ordering or purchasing ARTVIGIL 250, it is necessary to consult a physician who will confirm indications, rule out contraindications, and explain the administration scheme. Efficacy and tolerability depend on the individual response of the body, concomitant diseases, and other medications. Self-medication with armodafinil can be dangerous even with formally "typical" symptoms of sleepiness. Keep the package insert and contact a specialist if any undesirable effects appear. A responsible approach to purchasing and use is the basis for the safe application of ARTVIGIL 250.